LDLR-Primed LRP1 Transcytosis with pH-Activated Endosomal Escape

This strategy combines LDLR upregulation in brain endothelial cells with engineered LRP1-targeting antibodies containing pH-responsive endosomal escape mechanisms for enhanced CNS delivery. The approach begins with targeted pharmacological or gene therapy-mediated upregulation of LDLR expression in brain capillary endothelium, which primes the cholesterol transport machinery and creates a metabolically active endothelial environment that enhances LRP1 receptor cycling and transcytotic capacity. Therapeutic antibodies are conjugated to high-affinity APOE-mimetic peptides that specifically bind LRP1, ensuring rapid receptor-mediated endocytosis into brain endothelial cells via the well-characterized apolipoprotein pathway.

This strategy combines LDLR upregulation in brain endothelial cells with engineered LRP1-targeting antibodies containing pH-responsive endosomal escape mechanisms for enhanced CNS delivery. The approach begins with targeted pharmacological or gene therapy-mediated upregulation of LDLR expression in brain capillary endothelium, which primes the cholesterol transport machinery and creates a metabolically active endothelial environment that enhances LRP1 receptor cycling and transcytotic capacity. Therapeutic antibodies are conjugated to high-affinity APOE-mimetic peptides that specifically bind LRP1, ensuring rapid receptor-mediated endocytosis into brain endothelial cells via the well-characterized apolipoprotein pathway. The critical innovation involves engineering these antibody conjugates with pH-sensitive fusogenic peptides that remain inactive at physiological pH (7.4) but undergo conformational activation in the acidic endosomal environment (pH 5.5-6.0). Upon endocytic uptake, the decreasing endosomal pH triggers the fusogenic peptides to disrupt endosomal membranes, facilitating antibody escape before lysosomal targeting and degradation. The LDLR upregulation creates a synergistic effect by increasing overall endothelial transcytotic machinery, cholesterol trafficking proteins, and membrane recycling processes that support efficient LRP1-mediated transport. This dual-mechanism approach addresses both BBB penetration limitations and post-transcytotic degradation, potentially achieving 50-500 fold improvements in CNS antibody bioavailability. The strategy leverages quantifiable LRP1 kinetics and LDLR expression levels, providing predictable pharmacokinetic properties independent of variable FcRn transport efficiency. This approach is particularly suitable for neurodegenerative disease therapeutics requiring sustained CNS exposure, as it transforms degradative endosomal trafficking into a productive delivery pathway while maintaining antibody structural integrity and therapeutic activity.